The RNAseq of 79 small cell lung cancer (sclc) and 7 normal control

ABSTRACT: Even though small cell lung cancer (SCLC) has entered the age of broad genomic analysis, platinum-based chemotherapy remains the standard care for SCLC. Topotecan is the only approved agent for recurrent or progressive SCLC (1). In the absence of well-defined genomic biomarkers, clinical efficacy signals in genomically distinct subsets of SCLC could have been missed. Serine/Arginine Splicing Factor 1 (SRSF1) is a member of SR protein family. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation (2). Whole exome and transcriptome sequencing of primary tumor SCLC from 99 Chinese patients has identified SRSF1 DNA amplification and mRNA over-expression which pr

ORGANISM(S): Homo sapiens

SUBMITTER: Dong Shen 

PROVIDER: E-GEOD-60052 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress